3,090 patients with coronary heart disease (CHD) aged < 74 years (2,825 men, 265 women)
on entry total cholesterol 4.7 mmol/L-6.5mmol/L, triglyceride <3.4 mmol/L, HDL-c <1.16 mmol/L
treatment - bezafibrate 400mg per day or placebo
mean follow-up 6.2 years
no significant effect of bezafibrate on combined incidence of non-fatal MI or death from CHD
post-hoc subgroup analysis indicated the possibility of a substantially greater benefit of bezafibrate in the subset of patients with a baseline plasma triglyceride > 2.25 mmol/L - in this subgroup event rate was 12.0% in the bezafibrate group and 19.7% in the placebo group (relative reduction of 39% (p=0.02))
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.